As an innovative enterprise in the IVD industry,Sh
Leukemia, malignant lymphoma, and multiple myeloma are common hematological tumors. Minimal residual disease (MRD) refers to the state where a small amount of leukemia cells remain in the body after treatment and remission of these hematological tumors, which is an important cause of leukemia recurrence. Accurate MRD detection can early predict leukemia recurrence, stratify patient risk levels, guide post remission treatment, and determine the optimal time for bone marrow or stem cell transplantation.
The 2020 version of the CSCO lymphoma diagnosis and treatment guidelines states that Ig/TCR clonal rearrangement testing can assist in: ① lesions that are difficult to distinguish between benign and malignant; ② Suspected lymphoma; ③ Diagnosis and differentiation of certain specific diseases; ④ Tumors with complex cell composition or difficult to distinguish cell lines with immune markers; ⑤ Tumor cloning correlation analysis; ⑥ Assessment of minimal residual lesions.
FAIR-SEQ ™ (Fast&Accurate Immune Repertoire Sequencing) This series of test kits adopts an experimental system optimized based on synthetic templates. After multiple rounds of optimization and adjustment of the primer system, the amplification deviation of the majority of primers in the adjusted experimental system is within one time, which can accurately reflect the true clone distribution of the sample. For specific content, please refer to the following detailed introduction.
CAR-T cell immunotherapy has attracted significant attention both domestically and abroad due to its remarkable therapeutic effects in treating hematological malignancies. Accurately assessing, monitoring, and managing these therapies in the complex clinical setting of CAR-T treatment is a major challenge. Immune profiling sequencing technology enables digital evaluation and monitoring of the treatment process and outcomes by analyzing the dynamic changes of three cell types: tumor cells (for efficacy evaluation through MRD monitoring), CAR-T cells (for monitoring CAR-T expansion and persistence), and newly generated autologous immune cells (for immune reconstitution).
Chimeric antigen receptor T-cell (CAR-T) immunotherapy has become a hot research topic both domestically and internationally due to its significant therapeutic effects in treating hematological malignancies. Accurately assessing, monitoring, and managing CAR-T therapy in the complex clinical environment of CAR-T treatment presents a major challenge. Immune profiling sequencing technology can digitally evaluate and monitor the treatment process and outcomes by tracking the dynamic changes of three types of cells: tumor cells (for efficacy assessment through MRD monitoring), CAR-T cells (for monitoring CAR-T expansion and persistence), and newly generated autologous immune cells (for immune reconstitution).
Shenzhen Neoimmune Co., Ltd is a platform provider that provides data and technology in the field of immunology precision medicine and has successively been recognized as a national high-tech enterprise, Shenzhen innovative small and medium-sized enterprise, and Shenzhen science and technology small and medium-sized enterprise.
MORE8/F, Block A, Hengtemei Building, No. 3 Ganli Road, Longgang District, Shenzhen; 402, Kelente R&D Building, Ganli Road, Longgang District, Shenzhen.